AADI VS PMVP Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilitySentiment
PerformanceTechnicalsEarningsProfitVolatilitySentiment

Performance

AADI
10/100

AADI returned -64.24% in the last 12 months. Based on SPY's performance of -13.86%, its performance is below average giving it a score of 10 of 100.

PMVP
10/100

PMVP returned -82.93% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

Technicals

AADI
57/100

AADI receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

PMVP
43/100

PMVP receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

AADI
10/100

AADI has missed earnings 9 times in the last 20 quarters.

PMVP
49/100

PMVP has missed earnings 3 times in the last 20 quarters.

Profit

AADI
13/100

Out of the last 20 quarters, AADI has had 2 profitable quarters and has increased their profits year over year on 2 of them.

PMVP
10/100

Out of the last 17 quarters, PMVP has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

AADI
39/100

AADI has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

PMVP
33/100

PMVP has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

Sentiment

AADI

"Sentiment" not found for AADI

PMVP
68/100

PMVP had a bullish sentiment score of 68.36% across Twitter and StockTwits over the last 12 months. It had an average of 10.94 posts, 3.32 comments, and 11.68 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Aadi Bioscience, Inc. Common Stock Summary

Nasdaq / AADI
Healthcare
Biotechnology
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

PMV Pharmaceuticals, Inc Summary

Nasdaq / PMVP
Healthcare
Biotechnology
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.